

# Antonio Nicolucci

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5238607/publications.pdf>

Version: 2024-02-01

75  
papers

3,316  
citations

201674

27  
h-index

155660

55  
g-index

79  
all docs

79  
docs citations

79  
times ranked

4895  
citing authors

#	ARTICLE	IF	CITATIONS
1	Is it time to consider depression as a major complication of type 2 diabetes? Evidence from a large population-based cohort study. <i>Acta Diabetologica</i> , 2022, 59, 95-104.	2.5	9
2	Effect of a Behavioural Intervention for Adoption and Maintenance of a Physically Active Lifestyle on Psychological Well-Being and Quality of Life in Patients with Type 2 Diabetes: The IDES_2 Randomized Clinical Trial. <i>Sports Medicine</i> , 2022, 52, 643-654.	6.5	5
3	Incidence rates and predictors of microvascular and macrovascular complications in patients with type 2 diabetes: Results from the longitudinal global discover study. <i>American Heart Journal</i> , 2022, 243, 232-239.	2.7	14
4	Accuracy of the Standard GlucoNavii Mentor in Blood Glucose Monitoring According to International Organization for Standardization 15197:2013 Criteria. <i>JMIR Diabetes</i> , 2022, 7, e20774.	1.9	0
5	The adolescent with obesity: what perspectives for treatment?. <i>Italian Journal of Pediatrics</i> , 2022, 48, 9.	2.6	29
6	Quality of life in people with type 2 diabetes in the 3 years following initiation of second-line therapy: The DISCOVER study. <i>Diabetes Research and Clinical Practice</i> , 2022, 185, 109218.	2.8	4
7	Compatibility of PiC Insupen Needles with a Broad Range of Pens for the Injection of Subcutaneously Administered Drugs for Diabetes. <i>Medical Devices: Evidence and Research</i> , 2022, Volume 15, 71-77.	0.8	0
8	Socioeconomic Factors Associated With Glycemic Measurement and Poor HbA1c Control in People With Type 2 Diabetes: The Global DISCOVER Study. <i>Frontiers in Endocrinology</i> , 2022, 13, 831676.	3.5	7
9	Factors associated with weight loss in people with overweight or obesity living with type 2 diabetes mellitus: Insights from the global DISCOVER study. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 1734-1740.	4.4	0
10	Comparative effectiveness of Glargine 300 U/mL vs. Degludec 100 U/mL in patients with type 2 diabetes switching from 1 <sup>st</sup> generation basal insulins. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2022, , .	2.6	1
11	Independent association of atherogenic dyslipidaemia with all-cause mortality in individuals with type 2 diabetes and modifying effect of gender: a prospective cohort study. <i>Cardiovascular Diabetology</i> , 2021, 20, 28.	6.8	6
12	Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. <i>BMJ, The</i> , 2021, 372, m4573.	6.0	322
13	Clinical profiles and quality of care of subjects with type 2 diabetes according to their cardiovascular risk: an observational, retrospective study. <i>Cardiovascular Diabetology</i> , 2021, 20, 59.	6.8	23
14	Lower risk of death and cardiovascular events in patients with diabetes initiating glucagon-like peptide-1 receptor agonists or sodium-glucose cotransporter-2 inhibitors: A real-world study in two Italian cohorts. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1484-1495.	4.4	20
15	Associations between second-line glucose-lowering combination therapies with metformin and HbA1c, body weight, quality of life, hypoglycaemic events and glucose-lowering treatment intensification: The DISCOVER study. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1823-1833.	4.4	7
16	Glycated Albumin for Glycemic Control in T2DM Population: A Multi-Dimensional Evaluation. <i>ClinicoEconomics and Outcomes Research</i> , 2021, Volume 13, 453-464.	1.9	2
17	Inappropriate intensification of glucose-lowering treatment in older patients with type 2 diabetes: the global DISCOVER study. <i>BMJ Open Diabetes Research and Care</i> , 2021, 9, e001585.	2.8	4
18	Prevalence and progression of chronic kidney disease among patients with type 2 diabetes: Insights from the DISCOVER study. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1956-1960.	4.4	8

#	ARTICLE	IF	CITATIONS
19	Early versus late intensification of glucose-lowering therapy in patients with type 2 diabetes: Results from the DISCOVER study. <i>Diabetes Research and Clinical Practice</i> , 2021, 178, 108947.	2.8	3
20	Effects of weight loss medications on mortality and cardiovascular events: A systematic review of randomized controlled trials in adults with overweight and obesity. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2021, 31, 2587-2595.	2.6	7
21	Perceived Benefits, Barriers, and Facilitators of a Digital Patient-Reported Outcomes Tool for Routine Diabetes Care: Protocol for a National, Multicenter, Mixed Methods Implementation Study. <i>JMIR Research Protocols</i> , 2021, 10, e28391.	1.0	4
22	Effectiveness of <i>Ascophyllum nodosum</i> and <i>Fucus vesiculosus</i> on Metabolic Syndrome Components: A Real-World, Observational Study. <i>Journal of Diabetes Research</i> , 2021, 2021, 1-8.	2.3	6
23	Health-related quality of life in patients with type 2 diabetes initiating a second-line glucose-lowering therapy: The DISCOVER study. <i>Diabetes Research and Clinical Practice</i> , 2021, 180, 108974.	2.8	3
24	Comparative Effectiveness of Switching From First-Generation Basal Insulin to Gargine 300 U/ml or Degludec 100 U/ml in Type 1 Diabetes: The RESTORE-1 Study. <i>Diabetes Therapy</i> , 2021, 12, 509-525.	2.5	11
25	Temporal trends in intensification of glucose-lowering therapy for type 2 diabetes in Italy: Data from the AMD Annals initiative and their impact on clinical inertia. <i>Diabetes Research and Clinical Practice</i> , 2021, 181, 109096.	2.8	6
26	Design and rationale of DISCOVER global registry in type 2 diabetes: Real-world insights of treatment patterns and its relationship with cardiovascular, renal, and metabolic multimorbidities. <i>Journal of Diabetes and Its Complications</i> , 2021, 35, 108077.	2.3	3
27	Clinical profiles and quality of care of adults with type 1 diabetes according to their cardiovascular Risk: A Multicenter, Observational, retrospective study. <i>Diabetes Research and Clinical Practice</i> , 2021, 182, 109131.	2.8	3
28	Glycaemic control in patients with type 2 diabetes initiating second-line therapy: Results from the global DISCOVER study programme. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 66-78.	4.4	20
29	Rapid-Acting Insulin Analogues Versus Regular Human Insulin: A Meta-Analysis of Effects on Glycemic Control in Patients with Diabetes. <i>Diabetes Therapy</i> , 2020, 11, 573-584.	2.5	25
30	Renal hyperfiltration is independently associated with increased all-cause mortality in individuals with type 2 diabetes: a prospective cohort study. <i>BMJ Open Diabetes Research and Care</i> , 2020, 8, e001481.	2.8	22
31	Clinical Outcomes of Switching to Insulin Gargine 300 U/ml from Other Basal Insulins in People with Type 2 Diabetes in Italy: A Real-World Study. <i>Diabetes Therapy</i> , 2020, 11, 2283-2298.	2.5	3
32	Association between On-Treatment Haemoglobin A1c and All-Cause Mortality in Individuals with Type 2 Diabetes: Importance of Personalized Goals and Type of Anti-Hyperglycaemic Treatment. <i>Journal of Clinical Medicine</i> , 2020, 9, 246.	2.4	2
33	Switch from intravenous or intramuscular to subcutaneous hepatitis B immunoglobulin: effect on quality of life after liver transplantation. <i>Health and Quality of Life Outcomes</i> , 2020, 18, 99.	2.4	3
34	Generalizability of Cardiovascular Safety Trials on SGLT2 Inhibitors to the Real World: Implications for Clinical Practice. <i>Advances in Therapy</i> , 2019, 36, 2895-2909.	2.9	11
35	Treatment patterns and associated factors in 14 668 people with type 2 diabetes initiating a second-line therapy: Results from the global DISCOVER study programme. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 2474-2485.	4.4	36
36	<p>Penetration force and cannula sliding profiles of different pen needles: the PICASSO study</p>. <i>Medical Devices: Evidence and Research</i> , 2019, Volume 12, 311-317.	0.8	8

#	ARTICLE	IF	CITATIONS
37	Incidence of severe hypoglycemia and possible associated factors in pediatric patients with type 1 diabetes mellitus in the real-life, post-DCCT setting: a systematic review. <i>Pediatric Diabetes</i> , 2019, 20, 678-692.	2.9	7
38	Effect of a Behavioral Intervention Strategy on Sustained Change in Physical Activity and Sedentary Behavior in Patients With Type 2 Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 880.	7.4	89
39	Treatment of type 2 diabetes mellitus worldwide: Baseline patient characteristics in the global DISCOVER study. <i>Diabetes Research and Clinical Practice</i> , 2019, 151, 20-32.	2.8	63
40	Overall Quality of Care Predicts the Variability of Key Risk Factors for Complications in Type 2 Diabetes: An Observational, Longitudinal Retrospective Study. <i>Diabetes Care</i> , 2019, 42, 514-519.	8.6	28
41	Urban diabetes: the case of the metropolitan area of Rome. <i>Acta Biomedica</i> , 2019, 90, 209-214.	0.3	7
42	Haemoglobin A1c variability is a strong, independent predictor of all-cause mortality in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 1885-1893.	4.4	45
43	Long-Term Effectiveness of Liraglutide for Treatment of Type 2 Diabetes in a Real-Life Setting: A 24-Month, Multicenter, Non-interventional, Retrospective Study. <i>Advances in Therapy</i> , 2018, 35, 243-253.	2.9	19
44	Cost-effectiveness of sensor-augmented pump therapy in two different patient populations with type 1 diabetes in Italy. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2018, 28, 707-715.	2.6	11
45	Patterns of glycaemic control in patients with type 2 diabetes mellitus initiating second-line therapy after metformin monotherapy: retrospective data for 10%256 individuals from the United Kingdom and Germany. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 389-399.	4.4	38
46	Vascular complications in patients with type 2 diabetes: prevalence and associated factors in 38 countries (the DISCOVER study program). <i>Cardiovascular Diabetology</i> , 2018, 17, 150.	6.8	149
47	Obesity in Germany and Italy: prevalence, comorbidities, and associations with patient outcomes. <i>ClinicoEconomics and Outcomes Research</i> , 2018, Volume 10, 457-475.	1.9	17
48	Efficacy, safety and acceptability of the new pen needle 34Gx3.5mm: a crossover randomized non-inferiority trial; AGO 02 study. <i>Current Medical Research and Opinion</i> , 2018, 34, 1699-1704.	1.9	3
49	Real-world use of self-monitoring of blood glucose in people with type 2 diabetes: an urgent need for improvement. <i>Acta Diabetologica</i> , 2018, 55, 1059-1066.	2.5	16
50	A multistep approach for the stratification of the risk of severe hypoglycemia in patients with type 2 diabetes. <i>Minerva Endocrinology</i> , 2018, 43, 501-510.	1.1	7
51	Variability in HbA1c, blood pressure, lipid parameters and serum uric acid, and risk of development of chronic kidney disease in type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 1570-1578.	4.4	70
52	Towards an improved global understanding of treatment and outcomes in people with type 2 diabetes: Rationale and methods of the DISCOVER observational study program. <i>Journal of Diabetes and Its Complications</i> , 2017, 31, 1188-1196.	2.3	46
53	Effect of a Behavioral Intervention Strategy for Adoption and Maintenance of a Physically Active Lifestyle: The Italian Diabetes and Exercise Study 2 (IDES_2). <i>Diabetes Care</i> , 2017, 40, 1444-1452.	8.6	26
54	Beneficial effect of lixisenatide after 76 weeks of treatment in patients with type 2 diabetes mellitus: A meta-analysis from the GetGoal programme. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 248-256.	4.4	6



#	ARTICLE	IF	CITATIONS
73	Quality of diabetes care predicts the development of cardiovascular events: Results of the QuED study. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2008, 18, 57-65.	2.6	37
74	The Italian Diabetes and Exercise Study (IDES): Design and methods for a prospective Italian multicentre trial of intensive lifestyle intervention in people with type 2 diabetes and the metabolic syndrome. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2008, 18, 585-595.	2.6	50
75	Baseline Quality-of-Care Data From a Quality-Improvement Program Implemented by a Network of Diabetes Outpatient Clinics. <i>Diabetes Care</i> , 2008, 31, 2166-2168.	8.6	61